BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33527855)

  • 1. The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis.
    Wang Z; Yang J; Zhu W; Tang Y; Jia J
    Int J Neurosci; 2022 Dec; 132(12):1245-1253. PubMed ID: 33527855
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.
    Liu W; Lin H; He X; Chen L; Dai Y; Jia W; Xue X; Tao J; Chen L
    Transl Psychiatry; 2020 Apr; 10(1):125. PubMed ID: 32350238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
    Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
    J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
    Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis.
    Yoong SQ; Lu J; Xing H; Gyanwali B; Tan YQ; Wu XV
    Ageing Res Rev; 2021 Dec; 72():101491. PubMed ID: 34688925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment.
    Mavroudis IA; Petridis F; Chatzikonstantinou S; Kazis D
    Aging Clin Exp Res; 2020 Sep; 32(9):1639-1646. PubMed ID: 31463927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
    Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
    Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
    Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
    De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
    J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
    Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
    Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurogranin in Alzheimer's disease and ageing: A human post-mortem study.
    Saunders T; Gunn C; Blennow K; Kvartsberg H; Zetterberg H; Shenkin SD; Cox SR; Deary IJ; Smith C; King D; Spires-Jones T
    Neurobiol Dis; 2023 Feb; 177():105991. PubMed ID: 36623608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurogranin as a predictor of memory and executive function decline in MCI patients.
    Headley A; De Leon-Benedetti A; Dong C; Levin B; Loewenstein D; Camargo C; Rundek T; Zetterberg H; Blennow K; Wright CB; Sun X;
    Neurology; 2018 Mar; 90(10):e887-e895. PubMed ID: 29429972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
    Wang L;
    Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Dulewicz M; Kulczyńska-Przybik A; Mroczko B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.